Between January 2016 and May 2019, you recorded approximately 397 customer complaints related to container closure issues (e.g., approximately 60%), product separation, lack of effect and adverse events. Your quality unit failed to adequately review these complaints, identify trends, and implement effective CAPAs. During the inspection you explained that these lapses in quality system performance were due to underperforming staff, who had since been dismissed. In your response, you attributed these and other quality related issues to under staffing of the quality unit as your business expanded.
Your response is inadequate because you failed to appropriately address your quality unit not performing their required duties. Your firm must provide the quality unit with the appropriate authority, sufficient resources, and staff to carry out its responsibilities to consistently ensure drug quality.FDA Warning Letter to Teligent Pharma, Inc. dated 26-November-2019
Continuing the trend of making me petrified about generics, this warning letter is a roller-coaster read. One big set of failures is to actually investigate and apply appropriate resources to the quality unit. And then the management had the gall to blame the employees.
80+ years of quality principles ignored. I personally thought the FDA was being overly nice.
There are basically three questions to answer:
- Do you have a properly established, staffed, and managed Quality Unit?
- Does your Quality Unit have appropriate responsibilities and authority?
- Does your Quality Unit have access to the data it needs to make informed decisions?